2983753
Descripción
Fichas por lola_smily, actualizado hace más de 1 año
|
Creado por lola_smily
hace más de 9 años
|
|
| Pregunta | Respuesta |
| Acetylcholine -muscarinic receptor agonist | |
| Metacholine - muscarinic receptor agonist - modification of the ethylene bridge - S(+) equipotent to ACH - beta methyl substitution => more selective to Muscarininc receptor - more resistant to AChE => slow hydrolysis | |
| Carbachol -muscarinic receptor agonist - modification of the acetoxy group - converting ester to carbamate - similar ACh potency, same profile -hydrolysis by AChE | |
| Bethanechol - muscarinic receptor agonist - beta methyl substitution - potent and selective Muscarinic agonist -S(+) more potent | |
| choline ethyl ether - muscarinic receptor agonist - exception to the classical SAR of muscarinic activity | |
| alkyl amino ketones - muscarinic receptor agonist - exception to the classical SAR of muscarinic activity | |
| L(+)- Muscarine Chloride | |
| epimuscarine | |
| pilocarpine - alkaloid, produced from Pilocarpus jaborandi - Potent muscarinic agonist - chemically unstable => ring opening | |
| pilocarpic acid - inactive - product of hydrolysis of pilocarpine | |
| isopilocarpine - epimerization of pilocarpine - inactive product | |
| Physostigmine -indirectly acting parasympathomimetics - reversible AChE - 3ary alkaloid obtained from the Calabar Bean, Physostigma venosum - exhibits high affinity to AChE of 10^-9 to carbachol of 10^-4 -used to treat glaucoma and over dose of anticholinergic -light sensitive -undergoes hydrolysis in aqueous solutions | |
| eseroline inactive degradation product of physostigmmine in aqueous solutions | |
| rubreserine -inactive degradation product of physostigmmine in aqueous solutions - red color | |
| neostigmine -indirectly acting parasympathomimetics - reversible AChE synthetic ionized -indicated for Myastenia Gravis | |
| pyridostigmine -indirectly acting parasympathomimetics - reversible AChE synthetic ionized -indicated for Myastenia Gravis | |
| donepezil hydrochloride -indirectly acting parasympathomimetics - reversible AChE - lack hepatotoxicity - used for Alzheimer's disease | |
| tacrine indirectly acting parasympathomimetics - reversible AChE - cause hepatotoxicity - used for Alzheimer's disease | |
| rivastigmine indirectly acting parasympathomimetics - reversible AChE - lack hepatotoxicity - used for Alzheimer's disease | |
| Edrophonium -used for diagnostic purposes - improve Myastenia Gravis -worsen cholinergic chrisis | |
| Malathion irreversible AChEi organophosphate thio group | |
| parathion irreversible AChEi organophosphate thio group low Anti-AChE activity | |
| sarin irreversible AChEi organophosphate | |
| paraoxon irreversible AChEi organophosphate oxo group high Anti-AChE activity | |
| echothiophate iodide irreversible AChEi organophosphate ionized => clnical application for glaucoma | |
| oxime reactivation of AChE | |
| Pralidoxime chloride (2 -PAM) reactivation of AChE | |
| obidoxime reactivation of AChE | |
| diacetylmonoxime reactivation of AChE | |
| atropine parasympatholytics muscarine receptor antagonist alkaloid obtained from atropa belladonna atropine also found in datura stramonium | |
| scopolamine parasympatholytics muscarine receptor antagonist alkaloid obtained from atropa belladonna aslo found in Hyascyamus niger | |
| glycopyrrolate -antiholinergic -amino alcohol ester -ionized, exert effect locally in GI | |
| propantheline antiholinergic -amino alcohol ester -ionized, exert effect locally in GI | |
| clinidium antiholinergic -amino alcohol ester -ionized, exert effect locally in GI | |
| ipratronium antiholinergic -amino alcohol ester -ionized, exert effect locally in GI | |
| flavoxate antiholinergic -amino alcohol ester -ionized, exert effect locally in GI | |
| oxyphencyclimine anticholinergic amino alcohol ester 3ary amine, used for Parkinson treatment systemic, can cross BBB | |
| procyclidine anticholinergic amino alcohol 3ary amine, systemic effect | |
| trihexyphenidyl anticholinergic amino alcohol 3ary amine, systemic effect | |
| benztropine anticholinergic amino ethers | |
| orphenadrine anticholinergic amino ether antihistaminic anticholinergic> antihistaminic | |
| pirenzepine - selective M1 receptor antagonist - they are competitive antagonists -have antispasmodic effects -produce mydriasis -antisecretory: -decrease gastric secretions -decrease saliva secretions -decrease bronchial secretions | |
| telenzepine selective M1 receptor antagonist - they are competitive antagonists -have antispasmodic effects -produce mydriasis -antisecretory: -decrease gastric secretions -decrease saliva secretions -decrease bronchial secretions | |
| hexamethonium - ganglionic blocking agent - bisquaternary ammonium -MOA: they block autonomic ganglia => inhibit ganglionic transmission - main therapeutic indication: antihypertensive | |
| trimethophan ganglionic blocking agent - sulfonium -MOA: they block autonomic ganglia => inhibit ganglionic transmission - main therapeutic indication: antihypertensive | |
| pentolinium ganglionic blocking agent - bisquaternary ammonium -MOA: they block autonomic ganglia => inhibit ganglionic transmission - main therapeutic indication: antihypertensive | |
| mecamylamine ganglionic blocking agent - secondary amines -MOA: they block autonomic ganglia => inhibit ganglionic transmission - main therapeutic indication: antihypertensive | |
| pempidine ganglionic blocking agent - tertiary amine -MOA: they block autonomic ganglia => inhibit ganglionic transmission - main therapeutic indication: antihypertensive | |
| succinylcholine chloride - depolarizing NMJ blocker - produce a 2 phase block phase 1: stimulation phase 2: depression block by receptor desensitization - therapeutic use : muscle relaxation - reversal of effects of depolarizing : give antagonist to sensitize the receptor | |
| tubocurarine - non depolarizing NMJ blocker - cc: benzylisoquinoline - they are competitive receptor antagonist - all are ionized - lack CNS side effect - therapeutic use: muscle relaxation - reversal of effects of non depolarizing: AChI | |
| atracurium besylate - non depolarizing NMJ blocker - cc: benzylisoquinoline - they are competitive receptor antagonist - all are ionized - Exception: CNS side effects - therapeutic use: muscle relaxation - reversal of effects of non depolarizing: AChI | |
| mivacurium chloride non depolarizing NMJ blocker - cc: benzylisoquinoline - they are competitive receptor antagonist - all are ionized - lack CNS side effect - therapeutic use: muscle relaxation - reversal of effects of non depolarizing: AChI | |
| doxacurium chloride non depolarizing NMJ blocker - cc: benzylisoquinoline - they are competitive receptor antagonist - all are ionized - lack CNS side effect - therapeutic use: muscle relaxation - reversal of effects of non depolarizing: AChI | |
| L-Tyrosine | |
| L-Dopa | |
| Dopamine | |
| Norepinephrine - released NE : binding to receptor postsynaptic and presynaotic uptake 1( recycling NE) uptake 2 ( degradation, metabolism ) - receptor selectivity: alpha 1, 2, beta 1 | |
| epinephrine - increasing the size of R1 ( CH3) increase beta and decrease alpha adrenergic activity - receptor activity: Beta 2 > alpha 1,2, beta 1 | |
| Isoproterenol increasing the size of R1 (isopropyl) increase beta and decrease alpha adrenergic activity - receptor activity: Beta 2, Beta 1 | |
| Colterol - increase the size of R1 to t-butyl group increase selectivity to beta 2 agonistic activity -cc: phenylethanolamines -receptor selectivity :beta 2 > beta 1 beta 2 agonist | |
| ritodrine -increasing the size of R1 => increase selectivity to beta 2 agonistic activity - at least one hydroxyl group is required to form hydrogen bonding with receptor | |
| Ethylnorepinephrine substation on Carbon 2, R2: ethyl increase beta activity chiral center at C2 -receptor activity: beta > alpha | |
| alpha- methylnorepinephrine (1R, 2S) 1R, 2S isomer : maximum direct activity 1R, 2R isomer: indirect activity receptor activity: alpha 2 > alpha 1 | |
| terbutaline 3', 5'- dihydroxy substitution: orally active no COMT metabolism receptor activity: beta 2> beta 1 | |
| albuterol 3' hydroxymethyl,4'hydroxy substitution non cathechol => orally active receptor activity: beta 2 > beta 1 | |
| Phenylephrine 3' hydroxyl substitution => alpha 1 activity | |
| Metaraminol 3' hydroxyl substitution => alpha 1 activity | |
| Methoxamine 2',5' -dimethoxy substitution => alpha 1 activity | |
| pirbuterol beta 2 agonist cc: phenylethanolamies | |
| salmeterol beta 2 agonist cc: phenylethanolamines | |
| bitolterol -beta 2 agonist - phenylethanolamine - non catechol : orally active - bi- toluoylester ( more lipophilic) - given by inhalation -hydrolyzed by esterase in the lungs to give colterol - twice the DOA than catechol | |
| Dobutamine (-) dobutamine : alpha agonist + beta 1 agonist (+) dobutamine: alpha antagonist + beta 1 agonist ( 10x) racemic mixture: selective beta 1 activity exception to SAR | |
| dopamine - not strictly adrenergic agonist - DA receptor agonist => dialates renal blood vessels - at higher dose acts on beta 1 receptor - at much higher dose acts on alpha 1 receptor - not orally active | |
| (+,-) ephedrine - mixed acting sympathomimetics - alkaloid from Ephedra species (Ma Huang) - non cathechol : orally active more lipophilic - 1R, 2S: direct + indirect acting -used as nasal decongestant - cc: phenylethanoloamines | |
| pseudoephedrine - 1S, 2R and 1S, 2S : indirectly acting sympathomimetics | |
| amphetamine indirectly acting sympathomimetics dextro> levo non cathechol: orally active no hydrolysis: no 0H, very lipophilic, CNS stimulant | |
| metamphetamine indirectly acting sympathomimetics dextro> levo non cathechol: orally active no hydrolysis: no 0H, very lipophilic, CNS stimulant | |
| propylhexedrine indirectly acting sympathomimetics same as metamphetamine dextro> levo non cathechol: orally active no hydrolysis: no 0H, very lipophilic, POTENT CNS stimulant | |
| xylometazoline - alpha 1 adrenergic agonists - cc: imidazoline derivatives - contain a carbon between C2 of imidazoline and a phenyl ring - contain phenylethylamine moiety ortho methyl: agonistic activity at alpha 1 and alpha 2 receptors - bulky group at para position: increase alpha 1 and decrease alpha 2 activity - mainly used as nasal decongestant | |
| oxymetazoline - alpha 1 adrenergic agonists - cc: imidazoline derivatives contain a carbon between C2 of imidazoline and a phenyl ring - contain phenylethanolamine moiety ortho methyl: agonistic activity at alpha 1 and alpha 2 receptors - bulky group at para position: increase alpha 1 and decrease alpha 2 activity - mainly used as nasal decongestant | |
| tetrahydrozoline alpha 1 adrenergic agonists - cc: imidazoline derivatives contain a carbon between C2 of imidazoline and a phenyl ring - contain phenylethylamine moiety ortho methyl: agonistic activity at alpha 1 and alpha 2 receptors - mainly used as nasal decongestant | |
| naphazoline alpha 1 adrenergic agonists - cc: imidazoline derivatives contain a carbon between C2 of imidazoline and a phenyl ring - contain phenylethylamine moiety ortho methyl: agonistic activity at alpha 1 and alpha 2 receptors - mainly used as nasal decongestant | |
| clonidine - potent alpha 2 adrenergic receptor agonist -cc: imidazoline derivatives - developed as nasal vasoconstrictor - produce marked hypotensive effects, maily centrally mediated throughpostsynaptic alpha2 adrenergic receptor - used as antihypertensive agent - effects on peripheral postsynaptic alpha 2 receptors: vasoconstriction - effects on peripheral presynaptic: negative feedback, decrease NE - pka 8.5, 80% ionized, 20% NI | |
| Apraclonidine alpha 2 adrenergic agonist imidazoline moiety | |
| brimonidine alpha 2 adrenergic agonist imidazoline moiety | |
| guanabenz potent alpha 2 adrenergic agonist non imidazoline, clonidine like same indication as clonidine | |
| guanfacine potent alpha 2 adrenergic agonist non imidazoline, clonidine like same indication as clonidine | |
| alpha -methyldopamine alpha 2\ adrenergic antagonist non imidazoline derivative undergoes bioinactivation | |
| phenoxybenzamine - adrenergic antagonist - irreversible alpha blocker - non selective ( alpha 1 and 2 ) - Beta-haloalkylamine derivative - slow onset of action: because it is a prodrug, must undergoe bioactivation ( alkylated receptor active ) -limited use in pheochromocytoma (cancer of adrenal medulla) | |
| tolazoline - adrenergic receptor antagonist - reversible - non selective ( blocks alpha 1 and 2 ) - similar to xylometazoline BUT no ortho substitution: no alpha agonistic effects - limited use in treatment of symptoms of pheochromocytoma - rapid onset of action | |
| phentolamine - adrenergic receptor antagonist - reversible - non selective ( blocks alpha 1 and 2 ) - limited use in treatment of symptoms of pheochromocytoma - rapid onset of action | |
| prazosin - selective alpha 1 receptor antagonist reversible - quinazoline derivative -contain 4-amoni-6-7-dimethoxyquinazoline ring connected to piperazine at C2 -lower Blood Pressure | |
| terazosin selective alpha 1 receptor antagonist reversible - quinazoline derivative -contain 4-amoni-6-7-dimethoxyquinazoline ring connected to piperazine at C2 -lower Blood Pressure | |
| doxazosin selective alpha 1 receptor antagonist reversible - quinazoline derivative -contain 4-amoni-6-7-dimethoxyquinazoline ring connected to piperazine at C2 -lower Blood Pressure | |
| tamsulosin selective alpha 1 receptor antagonist reversible high affinity to alpha 1 A subtype present in prostate gland => used to treat BHP ( benign prostatic hyperplasia) - cc: sulfonamide phenylpropylamine | |
| indoramin - reversible selective alpha 1 receptor antagonist and H1 (histamine) and 5receptor antagonistHT (serotonin) - indole derivative | |
| yohimbine - reversible selective alpha 2 blocker - indole alkaloid from Yohimbe bark - increase Blood Pressure AND Heart Rate - very limited use to treat male sexual impotency | |
| practolol - Beta adrenergic receptor antagonist - aryloxypropanolamine with p-acylamino -change of acylamino to ortho or meta => loss of selectivity - inhibited isoproterenol induced tachycardia with minimal effects on isoproterenol induced hypotension -withdrawn from the market due to visual loss | |
| pronethalol - beta adrenergic receptor antagonist non selective -arylethanolamine - no partial agonistic activity - carcinogenic in animals | |
| propranolol -aryloxypropanolamine -beta adrenergic receptor non selective -10X> potent -no partial agonistic activity -not carcinogenic - used in hypertension, agnia pectoris, arrhythmia, migraine | |
| bunolol -non selective beta adrenergic receptor antagonist | |
| carteolol -non selective beta adrenergic receptor antagonist | |
| metipranolol -non selective beta adrenergic receptor antagonist - exception para postion - ester hydrolysis=> short acting | |
| nadolol -non selective beta adrenergic receptor antagonist | |
| penbutolol -non selective beta adrenergic receptor antagonist | |
| pindolol -non selective beta adrenergic receptor antagonist | |
| sotalol -non selective beta adrenergic receptor antagonist - aryl sulfonamide ethanolamine derivative | |
| timolol -non selective beta adrenergic receptor antagonist | |
| acebutolol -selective beta 1 adrenergic receptor antagonist cardio slective | |
| atenolol -selective beta 1 adrenergic receptor antagonist cardio slective | |
| betaxolol - selective beta 1 adrenergic receptor antagonist cardio selective | |
| esmolol - selective beta 1 adrenergic receptor antagonist cardio slective | |
| metoprolol selective beta 1 adrenergic receptor antagonist cardio slective | |
| bisoprolol selective beta 1 adrenergic receptor antagonist cardio slective | |
| labetolol non selective beta blocker and alpha 1 blocker mixed acting | |
| carvedilol non selective beta blocker and alpha 1 blocker mixed acting | |
| metyrosine - drugs affecting NE biosynthesis - tyrosine hydroxylase inhibitor | |
| carbidopa - drugs affecting NE biosynthesis - L-Dopa decarboxylase inhibitor | |
| reserpine -drugs affecting NE storage ( catecholamine depleting agents) - indole alkaloid -isolated from Rauwolfa Serpentina - inhibit catecholamine storage in storage vesicle => depletion of catecholamines | |
| guanadrel - drugs affecting NE release ( adrenergic neuronal blocking agents) | |
| guanethidine - drugs affecting NE release ( adrenergic neuronal blocking agents) | |
| bretylium - drugs affecting NE release ( adrenergic neuronal blocking agents) | |
| ergot alkaloid - produced by calviceps purourea, a fungus that infects grains | |
| ergotamine - ergot alkaloid - produced by calviceps purourea, a fungus that infects grains -mixed agonist/ antagonist - potent smooth muscle contraction - also used for migraine treatment | |
| ergonovine -ergot alkaloid -mixed agonist/ antagonist - potent smooth muscle contraction - also used for migraine treatment - potent inducer of uterine - because of better bioavailability, used to replace ergotmaine | |
| methylergonovine -ergot alkaloid -mixed agonist/ antagonist - potent smooth muscle contraction - also used for migraine treatment - potent inducer of uterine - because of better bioavailability, used to replace ergotmaine | |
| methylseregide -ergot alkaloid -mixed agonist/ antagonist -mainly used for migraine treatment | |
| morphine - cc: phenantrene - teriary amine group, N-methyl: good agonist Removal of N-methyl: decrease activity increase size of alkyl group: antagonist | |
| phenanthrene | |
| benzoquinone -oxidation od morphine product | |
| codeine - weak mu agonist - potent antitussive agent -partial O-demethylated => morphine | |
| Heroin -3,6-diacetyl derivative of morphine - weak affinity to mu receptor -more lipophilic: penetrates BBB - hydrolyzed in the brain to give: 3-acetylmorphine (3-MAM) 6-acetylmorphine (6-MAM) - 6-MAM has potent mu agonist | |
| oxymorphone - 3-hydroxy-N-methyl derivative 10X as potent as morphine - 14 beta hydroxyl enhances mu agonist activity and decrease antitussive activity | |
| oxycodone -3-hydroxyl-N-methyl derivative same activity as morphine but better oral bioavailability - 14 beta hydroxyl enhances mu agonist activity and decrease antitussive activity | |
| naloxone - N-allyl oxymorphone - pure non selective opioid receptor antagonist | |
| nalorphine - N-allyl substitution for N-methyl 7,8-double bond reduction 6-keto reduction u | |
| morphinan - removal of 4,5 epoxide bridge (modification of E ring) | |
| levorphanol -removal of 4,5 epoxide bridge - 8X more potent mu receptor agonist | |
| butorphanol -removal of 4,5 epoxide bridge - mu antagonist and kappa agonist | |
| dextromethorphan -removal of 4,5 epoxide bridge (+) levorphanol = dextrophan - lacks analgesia - antitussive activity | |
| benzomorphans - lacks the epoxide ring and the C ring - retain opioid activity | |
| cyclazocine - R: N-cyclopropyl methyl - mixed agonist/ antagonist kappa agonist mu antagonist | |
| phenazocine - R: N-ethylphenyl -potent mu agonist about 10X> morphine | |
| pentazocine -R: N-methyl of 2-methyl-2-butene - mixed agonist/antagonist kappa agonistic activity: analgesic mu antagonistic activity -only one marketed in US | |
| metazocine -R: CH3 - mu agonist -metasocine > morphine | |
| meperidine - A and D ring analogs of morphine - cc: phenylpiperidine -first synthesized agent with mu agonist activity of 1/4 of morphine -short DOA (useful in some medical procedure) | |
| MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -damages DA neurons => parkinsonism - product of reversed ester of meperidine | |
| fentanyl - cc: anilidopiperidine - 80X> potent than morphine | |
| sufentanil - cc: anilidopiperidine - 10X> potent than fentanyl (fentanyl 80X> morphine) | |
| remifentanyl - cc: anilidopiperidine - 25X> potent than morphine | |
| alfentanil - cc: anilidopiperidine - 20X> potent than morphine | |
| methadone -cc: diphenylheptanone - orally active and long DOA - useful for maintenance therapy of opoids addicts and for pain suppression of terminally ill patients | |
| isomethadone | |
| diphenoxylate -cc: diphenylheptanone - structural modification of methadone -antidiarrheal opioids | |
| loperamide -cc: diphenylheptanone - structural modification of methadone -antidiarrheal opioids | |
| thebaine -oripavine derivative - from papaver bracteatum no activity as opioid agonist | |
| etorphine - oripavine derivative - 1000 X> morphine - severe respiratory depression -low therapeutic index in humans, used for veterinary medicine | |
| buprenorphine -orpavine derivative - 20-50X> morphine - mixed agonist / antagonist -does not produce tolerance and addiction | |
| tramadol - synthetic mu agonist - orally active - possess opioid and non opioid analgesic activity -analgesic not reversed by naloxone -O-dimethyl metabolite is 6X> parent drug -less respiratory depression than morphine | |
| dezocine -mixed agonist / antagonist -only primary amine opoid agent - exact receptor selectivity is not known - equipotent with morphine | |
| nalbuphine - N-cyclobutylmethyl substitution for N-methyl 7,8-double bond reduction 6 keto reduction -mu antagonist and kappa agonist | |
| naltrexone -N-cyclopropyl-methyl oxymorphone - pure non selective opioid antagonist |
¿Quieres crear tus propias Fichas gratiscon GoConqr? Más información.